印度生物技术公司PlasmaGen筹集了1.5亿卢比, 以扩大全球范围, 推动产品开发. Indian biotech PlasmaGen raises ₹150 crore to expand globally and boost product development.

PlasmaGen生物科学公司是一家以孟加拉为基地的生物制药公司,在ViNS生物产品领导的少数公平回合中筹集了150格朗,价值超过1 500格朗的公司。 PlasmaGen Biosciences, a Bengaluru-based biopharma company, raised ₹150 crore in a minority equity round led by ViNS Bioproducts, valuing the firm at over ₹1,500 crore. 这笔资金是2010年以来筹得的600欧元以上资金的一部分,将支持国际扩张、产品开发和加强业务。 The funding, part of over ₹600 crore raised since 2010, will support international expansion, product development, and strengthened operations. 该公司于2024年开始在Kolar的等离子分离设施进行商业运营,向印度各地和新兴市场的医院提供白蛋白和免疫球蛋白等血浆衍生疗法。 The company, which began commercial operations in 2024 at its plasma fractionation facility in Kolar, supplies plasma-derived therapies like albumin and immunoglobulins to hospitals across India and emerging markets. 它正在推动监管批准和确保全球进入的分销伙伴。 It is advancing regulatory approvals and securing distribution partners for global entry.